Want to see ANTX full AI Analyst Report?
Top Page
AN2 Therapeutics, Inc.
(NASDAQ:ANTX)
Select Model
Select Model
Rating:55Neutral
Price Target:
$4.50
▼(-20.49% Downside)
Action:Reiterated
Date:08/19/26
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses, and persistent cash burn despite zero debt). Offsetting factors include constructive technical momentum and a positive corporate catalyst from encouraging Chagas program trial results, while valuation support is limited due to negative earnings and no dividend.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet reduces interest expense, refinancing exposure, and financial pressure while the company develops its pipeline. This gives AN2 greater flexibility to direct available capital toward clinical programs and lowers the risk that lenders constrain operations during a prolonged development cycle.
Negative Factors
Pre-revenue business model
The absence of meaningful revenue leaves AN2 dependent on clinical progress and financing rather than internally generated operating funds. Until a candidate is approved and commercialized, the company has limited evidence of market monetization, making business performance highly sensitive to pipeline outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet reduces interest expense, refinancing exposure, and financial pressure while the company develops its pipeline. This gives AN2 greater flexibility to direct available capital toward clinical programs and lowers the risk that lenders constrain operations during a prolonged development cycle.
Read all positive factors
AN2 Therapeutics, Inc. (ANTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$166.04M
Dividend Yield17.05%
Average Volume (3M)257.77K
Price to Earnings (P/E)―
Beta (1Y)-0.33
Revenue GrowthN/A
EPS Growth13.97%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.07
Shares Outstanding37,736,237
10 Day Avg. Volume322,363
30 Day Avg. Volume257,768
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-1.15
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.68
Forecast
1Y Price Target
$9.00Price Target Upside59.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
AN2 Therapeutics, Inc. Business Overview & Revenue Model
Company Description
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole,...
AN2 Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -77.00K | 0.00 |
| EBITDA | -37.57M | -35.17M | 3.23M | 4.90M | -40.88M | -21.54M |
| Net Income | -36.28M | -35.17M | -51.32M | -64.73M | -40.96M | -21.54M |
Balance Sheet | ||||||
| Total Assets | 81.68M | 61.95M | 92.09M | 138.74M | 102.56M | 65.32M |
| Cash, Cash Equivalents and Short-Term Investments | 78.39M | 58.00M | 83.62M | 107.30M | 96.06M | 58.55M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 53.00K | 0.00 |
| Total Liabilities | 5.75M | 8.89M | 10.24M | 14.04M | 7.19M | 3.41M |
| Stockholders Equity | 75.92M | 53.06M | 81.85M | 124.70M | 95.37M | 61.91M |
Cash Flow | ||||||
| Free Cash Flow | -30.68M | -29.83M | -49.26M | -53.29M | -33.46M | -20.48M |
| Operating Cash Flow | -30.68M | -29.83M | -49.26M | -53.29M | -33.46M | -20.48M |
| Investing Cash Flow | 17.91M | 28.31M | 54.59M | -43.28M | -21.77M | -50.02M |
| Financing Cash Flow | 38.87M | 113.00K | 372.00K | 84.99M | 70.36M | 78.53M |
AN2 Therapeutics, Inc. Technical Analysis
Negative
5.66
Price Trends
5.51
Negative
5.09
Negative
3.87
Positive
Market Momentum
-0.16
Positive
32.53
Neutral
12.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANTX, the sentiment is Negative. The current price of 5.66 is above the 20-day moving average (MA) of 5.09, above the 50-day MA of 5.51, and above the 200-day MA of 3.87, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 32.53 is Neutral, neither overbought nor oversold. The STOCH value of 12.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANTX.
AN2 Therapeutics, Inc. Risk Analysis
AN2 Therapeutics, Inc. disclosed 71 risk factors in its most recent earnings report. AN2 Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AN2 Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $166.04M | -4.11 | -53.52% | 17.05% | ― | 13.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $150.96M | -1.35 | -57.92% | ― | -19.07% | 2.07% | |
46 Neutral | $254.43M | -4.82 | -99.17% | ― | -33.68% | 4.48% | |
45 Neutral | $151.84M | -0.11 | 250.02% | ― | ― | -2012.66% | |
44 Neutral | $138.12M | -5.70 | -21.11% | ― | ― | 73.28% | |
44 Neutral | $89.38M | -0.39 | -242.28% | ― | ― | 21.31% |
* Healthcare Sector Average
ANTX
AN2 Therapeutics, Inc.
4.40
3.14
249.21%
NERV
Minerva Neurosciences
3.18
0.65
25.69%
AVXL
Anavex Life Sciences
1.49
-7.13
-82.71%
VYGR
Voyager Therapeutics
2.45
-2.44
-49.90%
ACIU
AC Immune SA
2.50
-0.97
-27.95%
NMRA
Neumora Therapeutics, Inc.
0.48
-1.39
-74.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.